Featured Insights and Perspectives from Darwin

The latest insights, ideas, and perspectives from Darwin, updated weekly. Explore a cross-section of up-to-date content from us and other thought leaders on trends in health care, research, and data.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

News and Insights

Showing items 1 to3 of 6

Topics
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports
Insight
Our Take Newsletter
February 9, 2026

Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Learn More
February 9, 2026
Pharma strategy, engagement, and market access
Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations
Insight
Our Take Newsletter
February 2, 2026

Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Learn More
February 2, 2026
Health policy, CMS initiatives and health economics
Health insurance CEOs catch flak at House hearings on affordability, blame others for high costs
Insight
Our Take Newsletter
January 25, 2026

Health insurance CEOs catch flak at House hearings on affordability, blame others for high costs

Learn More
January 25, 2026
Health policy, CMS initiatives and health economics
Anthropic, OpenAI unveil new AI tools for health care enterprises
Insight
Our Take Newsletter
January 18, 2026

Anthropic, OpenAI unveil new AI tools for health care enterprises

Learn More
January 18, 2026
Digital health and emerging technologies
OpenAI introduces ChatGPT Health to further integrate users' health information
Insight
Our Take Newsletter
January 11, 2026

OpenAI introduces ChatGPT Health to further integrate users' health information

Learn More
January 11, 2026
Digital health and emerging technologies
FDA approves Novo Nordisk’s Wegovy pill
Insight
Our Take Newsletter
January 5, 2026

FDA approves Novo Nordisk’s Wegovy pill

Learn More
January 5, 2026
IDN trends, challenges, and leadership
Another 9 drugmakers agree to most-favored-nation pricing on certain products
Insight
Our Take Newsletter
December 22, 2025

Another 9 drugmakers agree to most-favored-nation pricing on certain products

Learn More
December 22, 2025
Health policy, CMS initiatives and health economics
Lilly’s ‘triple G’ candidate exceeds analysts’ expectations
Insight
Our Take Newsletter
January 14, 2026

Lilly’s ‘triple G’ candidate exceeds analysts’ expectations

Learn More
January 14, 2026
Pharma strategy, engagement, and market access
Eli Lilly achieves market value of $1 trillion
Insight
Our Take Newsletter
December 8, 2025

Eli Lilly achieves market value of $1 trillion

Learn More
December 8, 2025
Pharma strategy, engagement, and market access
Abbott to boost its diagnostics portfolio with $21 billion acquisition of Exact Sciences
Insight
Our Take Newsletter
November 24, 2025

Abbott to boost its diagnostics portfolio with $21 billion acquisition of Exact Sciences

Learn More
November 24, 2025
IDN trends, challenges, and leadership
CMS launches payment model to lower Medicaid drug spending
Insight
Our Take Newsletter
November 17, 2025

CMS launches payment model to lower Medicaid drug spending

Learn More
November 17, 2025
Health policy, CMS initiatives and health economics
Pfizer wins bidding war to acquire Metsera
Insight
Our Take Newsletter
November 10, 2025

Pfizer wins bidding war to acquire Metsera

Learn More
November 10, 2025
Pharma strategy, engagement, and market access
Stay Aware. Stay Informed.

Want to stay ahead of health care trends?

Sign up for highly curated, expert weekly strategic insights for health care executives and leaders.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.